Estrella Immunopharma’s (ESLA) “Sell (E+)” Rating Reaffirmed at Weiss Ratings

Estrella Immunopharma (NASDAQ:ESLA)‘s stock had its “sell (e+)” rating reaffirmed by Weiss Ratings in a note issued to investors on Wednesday,Weiss Ratings reports.

Separately, D. Boral Capital restated a “buy” rating and set a $16.00 target price on shares of Estrella Immunopharma in a report on Tuesday, August 12th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $16.00.

Estrella Immunopharma Price Performance

NASDAQ ESLA opened at $1.30 on Wednesday. Estrella Immunopharma has a fifty-two week low of $0.63 and a fifty-two week high of $1.78. The stock’s 50-day moving average is $1.04 and its two-hundred day moving average is $0.98. The firm has a market cap of $48.19 million, a P/E ratio of -5.00 and a beta of 0.39.

Estrella Immunopharma Company Profile

Estrella Immunopharma, Inc, a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia.